Vaxcyte, Inc. $PCVX Shares Acquired by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D lifted its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 20.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,658 shares of the company’s stock after buying an additional 11,181 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Vaxcyte were worth $2,401,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Norges Bank purchased a new position in Vaxcyte in the 2nd quarter worth approximately $32,109,000. Westfield Capital Management Co. LP raised its stake in shares of Vaxcyte by 42.4% during the second quarter. Westfield Capital Management Co. LP now owns 3,068,898 shares of the company’s stock valued at $99,770,000 after purchasing an additional 913,761 shares during the period. Qube Research & Technologies Ltd acquired a new position in shares of Vaxcyte during the second quarter worth $26,318,000. State Street Corp boosted its stake in shares of Vaxcyte by 12.1% in the second quarter. State Street Corp now owns 4,942,235 shares of the company’s stock valued at $160,672,000 after purchasing an additional 534,552 shares during the period. Finally, Eventide Asset Management LLC boosted its stake in shares of Vaxcyte by 80.4% in the second quarter. Eventide Asset Management LLC now owns 848,141 shares of the company’s stock valued at $27,573,000 after purchasing an additional 377,911 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Stock Up 2.1%

Shares of PCVX stock opened at $58.51 on Friday. The company has a market cap of $7.66 billion, a P/E ratio of -12.09 and a beta of 1.33. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $84.01. The business has a 50 day moving average of $50.05 and a two-hundred day moving average of $42.94.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PCVX shares. Guggenheim reissued a “buy” rating and issued a $116.00 price objective on shares of Vaxcyte in a research report on Monday, February 2nd. Needham & Company LLC increased their price target on Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th. BTIG Research restated a “buy” rating and set a $85.00 price objective on shares of Vaxcyte in a report on Monday, November 10th. Finally, Leerink Partners set a $77.00 target price on Vaxcyte and gave the company an “outperform” rating in a research note on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Vaxcyte has an average rating of “Moderate Buy” and a consensus price target of $93.83.

Insider Activity

In related news, insider Harpreet S. Dhaliwal sold 9,743 shares of the stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $46.69, for a total value of $454,900.67. Following the completion of the transaction, the insider owned 23,928 shares in the company, valued at $1,117,198.32. This represents a 28.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Elvia Cowan sold 11,623 shares of the firm’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $47.92, for a total transaction of $556,974.16. Following the transaction, the senior vice president owned 14,534 shares in the company, valued at $696,469.28. This represents a 44.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.